公开(公告)号：US20210024461A1

公开(公告)日：2021-01-28

申请号：US17066127

申请日：2020-10-08

申请人： Janssen Pharmaceutica NV

发明人： Cheng Yi Chen ,  Oliver Floegel ,  Michael Justus ,  Adrian Maurer ,  Karl Reuter ,  Tobias Strittmatter ,  Tobias Wedel

IPC分类号： C07C309/23 ,  C07C309/19 ,  C07C225/20

摘要： The present invention is directed to processes for the preparation of esketamine. The present invention is further directed to processes for the resolution of S-ketamine from a racemic or enantiomerically enriched mixture of ketamine. The present invention is further directed to an (S)-CSA salt of S-ketamine, more particularly a monohydrate form of the (S)-CSA salt of S-ketamine; and to an (R)-CSA salt of R-ketamine.

公开(公告)号：US10815196B2

公开(公告)日：2020-10-27

申请号：US15997267

申请日：2018-06-04

申请人： Janssen Pharmaceutica NV

发明人： Cheng Yi Chen ,  Oliver Floegel ,  Michael Justus ,  Adrian Maurer ,  Karl Reuter ,  Tobias Strittmatter ,  Tobias Wedel

IPC分类号： C07C309/23 ,  C07C309/19 ,  C07C225/20

摘要： The present invention is directed to processes for the preparation of esketamine. The present invention is further directed to processes for the resolution of S-ketamine from a racemic or enantiomerically enriched mixture of ketamine. The present invention is further directed to an (S)-CSA salt of S-ketamine, more particularly a monohydrate form of the (S)-CSA salt of S-ketamine; and to an (R)-CSA salt of R-ketamine.

公开(公告)号：US20180282266A1

公开(公告)日：2018-10-04

申请号：US15997267

申请日：2018-06-04

申请人： Janssen Pharmaceutica NV

发明人： Cheng Yi Chen ,  Oliver Floegel ,  Michael Justus ,  Adrian Maurer ,  Karl Reuter ,  Tobias Strittmatter ,  Tobias Wedel

IPC分类号： C07C309/23 ,  C07C309/19 ,  C07C225/20

摘要： The present invention is directed to processes for the preparation of esketamine. The present invention is further directed to processes for the resolution of S-ketamine from a racemic or enantiomerically enriched mixture of ketamine. The present invention is further directed to an (S)-CSA salt of S-ketamine, more particularly a monohydrate form of the (S)-CSA salt of S-ketamine; and to an (R)-CSA salt of R-ketamine.

公开(公告)号：US20160332962A1

公开(公告)日：2016-11-17

申请号：US15152705

申请日：2016-05-12

申请人： Janssen Pharmaceutica NV

发明人： Cheng Yi Chen ,  Oliver Floegel ,  Michael Justus ,  Adrian Maurer ,  Karl Reuter ,  Tobias Strittmatter ,  Tobias Wedel

IPC分类号： C07C309/23 ,  C07C225/20

CPC分类号： C07C309/23 ,  C07B2200/07 ,  C07B2200/13 ,  C07C225/20 ,  C07C309/19 ,  C07C2601/14 ,  C07C2602/42 ,  H05K999/99

摘要： The present invention is directed to processes for the preparation of esketamine. The present invention is further directed to processes for the resolution of S-ketamine from a racemic or enantiomerically enriched mixture of ketamine. The present invention is further directed to an (S)-CSA salt of S-ketamine, more particularly a monohydrate form of the (S)-CSA salt of S-ketamine, and to an (R)-CSA salt of R-ketamine.

摘要翻译： 本发明涉及制备西沙酮的方法。 本发明还涉及从氯胺酮的外消旋或对映体富集的混合物中分离S-氯胺酮的方法。 本发明还涉及S-氯胺酮的（S）-CSA盐，更特别是S-氯胺酮的（S）-CSA盐的一水合物形式和R-氯胺酮的（R）-CSA盐 。